Skip to main content
Erschienen in: Current Heart Failure Reports 5/2016

10.10.2016 | Biomarkers of Heart Failure (W H W Tang, Section Editor)

Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure

verfasst von: Shweta R. Motiwala, Hanna K. Gaggin

Erschienen in: Current Heart Failure Reports | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Left ventricular remodeling appears to be a critical link between cardiac injury and the development and progression of heart failure with reduced ejection fraction (HFrEF). Several drug and device therapies that modify and reverse the remodeling process in patients with HFrEF are closely associated with improvement in clinical outcomes. Reverse remodeling, including partial or complete recovery of systolic function and structure, is possible but its determinants are incompletely understood. Methods to predict reverse remodeling in response to therapy are not well defined. Though non-invasive imaging techniques remain the most widely used methods of assessing reverse remodeling, serum biomarkers are now being investigated as more specific, mechanistically driven, and clinically useful predictors of reverse remodeling. Biomarkers that reflect myocyte stretch and stress, myocyte injury and necrosis, inflammation and fibrosis, and extracellular matrix turnover may be particularly valuable for predicting pathophysiologic changes and prognosis in individual patients. Their use may ultimately allow improved application of precision medicine in chronic HF.
Literatur
2.
10.
11.
Zurück zum Zitat White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76(1):44–51.PubMedCrossRef White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76(1):44–51.PubMedCrossRef
13.
Zurück zum Zitat Mulvagh SL, DeMaria AN, Feinstein SB, Burns PN, Kaul S, Miller JG, et al. Contrast echocardiography: current and future applications. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2000;13(4):331–42.CrossRef Mulvagh SL, DeMaria AN, Feinstein SB, Burns PN, Kaul S, Miller JG, et al. Contrast echocardiography: current and future applications. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2000;13(4):331–42.CrossRef
14.
Zurück zum Zitat Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol. 2004;44(4):878–86. doi:10.1016/j.jacc.2004.05.050.PubMedCrossRef Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol. 2004;44(4):878–86. doi:10.​1016/​j.​jacc.​2004.​05.​050.PubMedCrossRef
15.
17.
Zurück zum Zitat Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327. doi:10.1161/CIR.0b013e31829e8776.CrossRef Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327. doi:10.​1161/​CIR.​0b013e31829e8776​.CrossRef
18.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847. doi:10.1093/eurheartj/ehs104.PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847. doi:10.​1093/​eurheartj/​ehs104.PubMedCrossRef
19.
Zurück zum Zitat Moe GW, Ezekowitz JA, O’Meara E, Lepage S, Howlett JG, Fremes S, et al. The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015;31(1):3–16. doi:10.1016/j.cjca.2014.10.022.PubMedCrossRef Moe GW, Ezekowitz JA, O’Meara E, Lepage S, Howlett JG, Fremes S, et al. The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015;31(1):3–16. doi:10.​1016/​j.​cjca.​2014.​10.​022.PubMedCrossRef
21.
Zurück zum Zitat Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997–1003. doi:10.1016/j.jacc.2008.04.069.PubMedCrossRef Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997–1003. doi:10.​1016/​j.​jacc.​2008.​04.​069.PubMedCrossRef
22.
Zurück zum Zitat Weiner RB, Baggish AL, Chen-Tournoux A, Marshall JE, Gaggin HK, Bhardwaj A, et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail. 2013;15(3):342–51. doi:10.1093/eurjhf/hfs180.PubMedCrossRef Weiner RB, Baggish AL, Chen-Tournoux A, Marshall JE, Gaggin HK, Bhardwaj A, et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail. 2013;15(3):342–51. doi:10.​1093/​eurjhf/​hfs180.PubMedCrossRef
23.
Zurück zum Zitat Gaggin HK, Truong QA, Rehman SU, Mohammed AA, Bhardwaj A, Parks KA, et al. Characterization and prediction of natriuretic peptide “nonresponse” during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail. 2013;19(3):135–42. doi:10.1111/chf.12016.PubMedCrossRef Gaggin HK, Truong QA, Rehman SU, Mohammed AA, Bhardwaj A, Parks KA, et al. Characterization and prediction of natriuretic peptide “nonresponse” during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail. 2013;19(3):135–42. doi:10.​1111/​chf.​12016.PubMedCrossRef
24.
Zurück zum Zitat Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Thanapiboonpol P, Nakyen S, Udompunturak S. Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. J Card Fail. 2008;14(8):687–94. doi:10.1016/j.cardfail.2008.05.002.PubMedCrossRef Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Thanapiboonpol P, Nakyen S, Udompunturak S. Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. J Card Fail. 2008;14(8):687–94. doi:10.​1016/​j.​cardfail.​2008.​05.​002.PubMedCrossRef
25.
Zurück zum Zitat Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Udompunturak S. NT-proBNP levels in the evaluation of right ventricular dysfunction in patients with coronary artery disease and abnormal left ventricular wall motion: a magnetic resonance imaging study. Coron Artery Dis. 2008;19(7):481–7. doi:10.1097/MCA.0b013e32830b4d0e.PubMedCrossRef Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Udompunturak S. NT-proBNP levels in the evaluation of right ventricular dysfunction in patients with coronary artery disease and abnormal left ventricular wall motion: a magnetic resonance imaging study. Coron Artery Dis. 2008;19(7):481–7. doi:10.​1097/​MCA.​0b013e32830b4d0e​.PubMedCrossRef
26.
Zurück zum Zitat Fruhwald FM, Fahrleitner-Pammer A, Berger R, Leyva F, Freemantle N, Erdmann E, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J. 2007;28(13):1592–7. doi:10.1093/eurheartj/ehl505.PubMedCrossRef Fruhwald FM, Fahrleitner-Pammer A, Berger R, Leyva F, Freemantle N, Erdmann E, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J. 2007;28(13):1592–7. doi:10.​1093/​eurheartj/​ehl505.PubMedCrossRef
27.
Zurück zum Zitat Januzzi Jr JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third universal definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J. 2012;33(18):2265–71. doi:10.1093/eurheartj/ehs191.PubMedCrossRef Januzzi Jr JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third universal definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J. 2012;33(18):2265–71. doi:10.​1093/​eurheartj/​ehs191.PubMedCrossRef
28.
Zurück zum Zitat Hudson MP, O’Connor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J. 2004;147(3):546–52. doi:10.1016/j.ahj.2003.10.014.PubMedCrossRef Hudson MP, O’Connor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J. 2004;147(3):546–52. doi:10.​1016/​j.​ahj.​2003.​10.​014.PubMedCrossRef
29.
Zurück zum Zitat Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001;103(3):369–74.PubMedCrossRef Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001;103(3):369–74.PubMedCrossRef
31.
Zurück zum Zitat Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol. 1999;84(5):608–11. A9.PubMedCrossRef Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol. 1999;84(5):608–11. A9.PubMedCrossRef
32.
Zurück zum Zitat Motiwala SR, Gaggin HK, Gandhi PU, Belcher A, Weiner RB, Baggish AL, et al. Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure. J Cardiovasc Transl Res. 2015;8(3):164–72. doi:10.1007/s12265-015-9618-4.PubMedCrossRef Motiwala SR, Gaggin HK, Gandhi PU, Belcher A, Weiner RB, Baggish AL, et al. Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure. J Cardiovasc Transl Res. 2015;8(3):164–72. doi:10.​1007/​s12265-015-9618-4.PubMedCrossRef
33.
Zurück zum Zitat Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol Intv. 2008;1(4):415–23. doi:10.1016/j.jcin.2008.04.010.CrossRef Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol Intv. 2008;1(4):415–23. doi:10.​1016/​j.​jcin.​2008.​04.​010.CrossRef
34.
Zurück zum Zitat Oh PC, Choi IS, Ahn T, Moon J, Park Y, Seo JG, et al. Predictors of recovery of left ventricular systolic dysfunction after acute myocardial infarction: from the korean acute myocardial infarction registry and korean myocardial infarction registry. Korean Circ J. 2013;43(8):527–33. doi:10.4070/kcj.2013.43.8.527.PubMedPubMedCentralCrossRef Oh PC, Choi IS, Ahn T, Moon J, Park Y, Seo JG, et al. Predictors of recovery of left ventricular systolic dysfunction after acute myocardial infarction: from the korean acute myocardial infarction registry and korean myocardial infarction registry. Korean Circ J. 2013;43(8):527–33. doi:10.​4070/​kcj.​2013.​43.​8.​527.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–6.PubMedPubMedCentralCrossRef Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–6.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721–6.PubMedCrossRef Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721–6.PubMedCrossRef
41.
Zurück zum Zitat Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, Vazquez R, Puig T, Valdes M, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009;54(23):2174–9. doi:10.1016/j.jacc.2009.07.041.PubMedCrossRef Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, Vazquez R, Puig T, Valdes M, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009;54(23):2174–9. doi:10.​1016/​j.​jacc.​2009.​07.​041.PubMedCrossRef
42.
Zurück zum Zitat Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdes Chavarri M, et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol. 2010;63(10):1171–8.PubMedCrossRef Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdes Chavarri M, et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol. 2010;63(10):1171–8.PubMedCrossRef
44.
Zurück zum Zitat Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail. 2012;14(3):268–77. doi:10.1093/eurjhf/hfs006.PubMedCrossRef Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail. 2012;14(3):268–77. doi:10.​1093/​eurjhf/​hfs006.PubMedCrossRef
45.
Zurück zum Zitat Bayes-Genis A, de Antonio M, Galan A, Sanz H, Urrutia A, Cabanes R, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012;14(1):32–8. doi:10.1093/eurjhf/hfr156.PubMedCrossRef Bayes-Genis A, de Antonio M, Galan A, Sanz H, Urrutia A, Cabanes R, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012;14(1):32–8. doi:10.​1093/​eurjhf/​hfr156.PubMedCrossRef
46.
Zurück zum Zitat Bayes-Genis A, de Antonio M, Vila J, Penafiel J, Galan A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;63(2):158–66. doi:10.1016/j.jacc.2013.07.087.PubMedCrossRef Bayes-Genis A, de Antonio M, Vila J, Penafiel J, Galan A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;63(2):158–66. doi:10.​1016/​j.​jacc.​2013.​07.​087.PubMedCrossRef
47.
49.
Zurück zum Zitat Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–50. doi:10.1016/j.jacc.2009.08.047.PubMedCrossRef Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–50. doi:10.​1016/​j.​jacc.​2009.​08.​047.PubMedCrossRef
51.
Zurück zum Zitat Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and Highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2(1):65–72. doi:10.1016/j.jchf.2013.10.005.PubMedCrossRef Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and Highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2(1):65–72. doi:10.​1016/​j.​jchf.​2013.​10.​005.PubMedCrossRef
52.
Zurück zum Zitat Lupon J, Sanders-van Wijk S, Januzzi JL, de Antonio M, Gaggin HK, Pfisterer M, et al. Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: a multicenter study. Int J Cardiol. 2016;204:242–7. doi:10.1016/j.ijcard.2015.11.163.PubMedCrossRef Lupon J, Sanders-van Wijk S, Januzzi JL, de Antonio M, Gaggin HK, Pfisterer M, et al. Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: a multicenter study. Int J Cardiol. 2016;204:242–7. doi:10.​1016/​j.​ijcard.​2015.​11.​163.PubMedCrossRef
58.
Zurück zum Zitat Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013;15(5):511–8. doi:10.1093/eurjhf/hfs205.PubMedCrossRef Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013;15(5):511–8. doi:10.​1093/​eurjhf/​hfs205.PubMedCrossRef
59.
Zurück zum Zitat Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol: Off J Ger Card Soc. 2010;99(5):323–8. doi:10.1007/s00392-010-0125-y.CrossRef Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol: Off J Ger Card Soc. 2010;99(5):323–8. doi:10.​1007/​s00392-010-0125-y.CrossRef
60.
Zurück zum Zitat Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013;15(10):1157–63. doi:10.1093/eurjhf/hft075.PubMedCrossRef Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013;15(10):1157–63. doi:10.​1093/​eurjhf/​hft075.PubMedCrossRef
61.
62.
Zurück zum Zitat Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J. 2012;164(6):878–83. doi:10.1016/j.ahj.2012.08.021.PubMedCrossRef Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J. 2012;164(6):878–83. doi:10.​1016/​j.​ahj.​2012.​08.​021.PubMedCrossRef
64.
Zurück zum Zitat Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol: Off J Ger Card Soc. 2013;102(2):103–10. doi:10.1007/s00392-012-0500-y.CrossRef Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol: Off J Ger Card Soc. 2013;102(2):103–10. doi:10.​1007/​s00392-012-0500-y.CrossRef
67.
Zurück zum Zitat Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012;33(18):2290–6. doi:10.1093/eurheartj/ehs077.PubMedCrossRef Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012;33(18):2290–6. doi:10.​1093/​eurheartj/​ehs077.PubMedCrossRef
69.
Zurück zum Zitat Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Am Heart J. 2015;169(3):404–11. doi:10.1016/j.ahj.2014.12.012. e3.PubMedCrossRef Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Am Heart J. 2015;169(3):404–11. doi:10.​1016/​j.​ahj.​2014.​12.​012. e3.PubMedCrossRef
70.
Zurück zum Zitat Stolen CM, Adourian A, Meyer TE, Stein KM, Solomon SD. Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Card Fail. 2014;20(11):793–9. doi:10.1016/j.cardfail.2014.07.018.PubMedCrossRef Stolen CM, Adourian A, Meyer TE, Stein KM, Solomon SD. Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Card Fail. 2014;20(11):793–9. doi:10.​1016/​j.​cardfail.​2014.​07.​018.PubMedCrossRef
71.
Zurück zum Zitat Lopez-Andres N, Rossignol P, Iraqi W, Fay R, Nuee J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012;14(1):74–81. doi:10.1093/eurjhf/hfr151.PubMedCrossRef Lopez-Andres N, Rossignol P, Iraqi W, Fay R, Nuee J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012;14(1):74–81. doi:10.​1093/​eurjhf/​hfr151.PubMedCrossRef
72.
Zurück zum Zitat Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2008;27(6):589–96. doi:10.1016/j.healun.2008.02.018.CrossRef Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2008;27(6):589–96. doi:10.​1016/​j.​healun.​2008.​02.​018.CrossRef
75.
Zurück zum Zitat Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley 3rd AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97(17):1708–15.PubMedCrossRef Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley 3rd AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97(17):1708–15.PubMedCrossRef
76.
Zurück zum Zitat Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Phys. 1998;274(5 Pt 2):H1516–23. Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Phys. 1998;274(5 Pt 2):H1516–23.
78.
Zurück zum Zitat Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004;109(23):2850–6. doi:10.1161/01.CIR.0000129318.79570.84.PubMedCrossRef Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004;109(23):2850–6. doi:10.​1161/​01.​CIR.​0000129318.​79570.​84.PubMedCrossRef
79.
Zurück zum Zitat Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106(1):55–62. doi:10.1172/JCI8768.PubMedPubMedCentralCrossRef Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106(1):55–62. doi:10.​1172/​JCI8768.PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Phys Heart Circ Phys. 2006;290(1):H232–9. doi:10.1152/ajpheart.00457.2005. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Phys Heart Circ Phys. 2006;290(1):H232–9. doi:10.​1152/​ajpheart.​00457.​2005.
81.
Zurück zum Zitat Zamilpa R, Ibarra J, de Castro Bras LE, Ramirez TA, Nguyen N, Halade GV, et al. Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol. 2012;53(5):599–608. doi:10.1016/j.yjmcc.2012.07.017.PubMedPubMedCentralCrossRef Zamilpa R, Ibarra J, de Castro Bras LE, Ramirez TA, Nguyen N, Halade GV, et al. Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol. 2012;53(5):599–608. doi:10.​1016/​j.​yjmcc.​2012.​07.​017.PubMedPubMedCentralCrossRef
82.
Zurück zum Zitat Li SW, Sieron AL, Fertala A, Hojima Y, Arnold WV, Prockop DJ. The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein-1. Proc Natl Acad Sci U S A. 1996;93(10):5127–30.PubMedPubMedCentralCrossRef Li SW, Sieron AL, Fertala A, Hojima Y, Arnold WV, Prockop DJ. The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein-1. Proc Natl Acad Sci U S A. 1996;93(10):5127–30.PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS. Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science. 1996;271(5247):360–2.PubMedCrossRef Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS. Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science. 1996;271(5247):360–2.PubMedCrossRef
84.
Zurück zum Zitat Vadon-Le Goff S, Hulmes DJ, Moali C. BMP-1/tolloid-like proteinases synchronize matrix assembly with growth factor activation to promote morphogenesis and tissue remodeling. Matrix Biol J Int Soc Matrix Biol. 2015;44–46:14–23. doi:10.1016/j.matbio.2015.02.006.CrossRef Vadon-Le Goff S, Hulmes DJ, Moali C. BMP-1/tolloid-like proteinases synchronize matrix assembly with growth factor activation to promote morphogenesis and tissue remodeling. Matrix Biol J Int Soc Matrix Biol. 2015;44–46:14–23. doi:10.​1016/​j.​matbio.​2015.​02.​006.CrossRef
85.
Zurück zum Zitat Kobayashi K, Luo M, Zhang Y, Wilkes DC, Ge G, Grieskamp T, et al. Secreted frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol. 2009;11(1):46–55. doi:10.1038/ncb1811.PubMedCrossRef Kobayashi K, Luo M, Zhang Y, Wilkes DC, Ge G, Grieskamp T, et al. Secreted frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol. 2009;11(1):46–55. doi:10.​1038/​ncb1811.PubMedCrossRef
86.
Zurück zum Zitat He W, Zhang L, Ni A, Zhang Z, Mirotsou M, Mao L, et al. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci U S A. 2010;107(49):21110–5. doi:10.1073/pnas.1004708107.PubMedPubMedCentralCrossRef He W, Zhang L, Ni A, Zhang Z, Mirotsou M, Mao L, et al. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci U S A. 2010;107(49):21110–5. doi:10.​1073/​pnas.​1004708107.PubMedPubMedCentralCrossRef
87.
Zurück zum Zitat Shalitin N, Schlesinger H, Levy MJ, Kessler E, Kessler-Icekson G. Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: evidence for co-regulation with type I collagen. J Cell Biochem. 2003;90(2):397–407. doi:10.1002/jcb.10646.PubMedCrossRef Shalitin N, Schlesinger H, Levy MJ, Kessler E, Kessler-Icekson G. Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: evidence for co-regulation with type I collagen. J Cell Biochem. 2003;90(2):397–407. doi:10.​1002/​jcb.​10646.PubMedCrossRef
89.
Zurück zum Zitat Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75(14):913–8.PubMedCrossRef Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75(14):913–8.PubMedCrossRef
91.
Zurück zum Zitat Lofsjogard J, Kahan T, Diez J, Lopez B, Gonzalez A, Edner M, et al. Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. J Cardiovasc Med. 2014;15(6):463–9. doi:10.2459/01.JCM.0000435617.86180.0b.CrossRef Lofsjogard J, Kahan T, Diez J, Lopez B, Gonzalez A, Edner M, et al. Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. J Cardiovasc Med. 2014;15(6):463–9. doi:10.​2459/​01.​JCM.​0000435617.​86180.​0b.CrossRef
92.
Zurück zum Zitat Poulsen SH, Host NB, Egstrup K. Long-term changes in collagen formation expressed by serum carboxyterminal propeptide of type-I procollagen and relation to left ventricular function after acute myocardial infarction. Cardiology. 2001;96(1):45–50.PubMedCrossRef Poulsen SH, Host NB, Egstrup K. Long-term changes in collagen formation expressed by serum carboxyterminal propeptide of type-I procollagen and relation to left ventricular function after acute myocardial infarction. Cardiology. 2001;96(1):45–50.PubMedCrossRef
93.
Zurück zum Zitat Luyt CE, Landivier A, Leprince P, Bernard M, Pavie A, Chastre J, et al. Usefulness of cardiac biomarkers to predict cardiac recovery in patients on extracorporeal membrane oxygenation support for refractory cardiogenic shock. J Crit Care. 2012;27(5):524 e7–14. doi:10.1016/j.jcrc.2011.12.009.PubMedCrossRef Luyt CE, Landivier A, Leprince P, Bernard M, Pavie A, Chastre J, et al. Usefulness of cardiac biomarkers to predict cardiac recovery in patients on extracorporeal membrane oxygenation support for refractory cardiogenic shock. J Crit Care. 2012;27(5):524 e7–14. doi:10.​1016/​j.​jcrc.​2011.​12.​009.PubMedCrossRef
94.
Zurück zum Zitat Ahmad T, Wang T, O’Brien EC, Samsky MD, Pura JA, Lokhnygina Y, et al. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. JACC Heart Fail. 2015;3(1):30–9. doi:10.1016/j.jchf.2014.06.013.PubMedCrossRef Ahmad T, Wang T, O’Brien EC, Samsky MD, Pura JA, Lokhnygina Y, et al. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. JACC Heart Fail. 2015;3(1):30–9. doi:10.​1016/​j.​jchf.​2014.​06.​013.PubMedCrossRef
95.
Zurück zum Zitat Lok SI, Nous FM, van Kuik J, van der Weide P, Winkens B, Kemperman H, et al. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support. Eur J Cardiothorac Surg Off J Eur Assoc Cardiothorac Surg. 2015;48(3):407–15. doi:10.1093/ejcts/ezu539.CrossRef Lok SI, Nous FM, van Kuik J, van der Weide P, Winkens B, Kemperman H, et al. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support. Eur J Cardiothorac Surg Off J Eur Assoc Cardiothorac Surg. 2015;48(3):407–15. doi:10.​1093/​ejcts/​ezu539.CrossRef
96.
97.
Zurück zum Zitat Hasin T, Kushwaha SS, Lesnick TG, Kremers W, Boilson BA, Schirger JA, et al. Early trends in N-terminal pro-brain natriuretic peptide values after left ventricular assist device implantation for chronic heart failure. Am J Cardiol. 2014;114(8):1257–63. doi:10.1016/j.amjcard.2014.07.056.PubMedCrossRef Hasin T, Kushwaha SS, Lesnick TG, Kremers W, Boilson BA, Schirger JA, et al. Early trends in N-terminal pro-brain natriuretic peptide values after left ventricular assist device implantation for chronic heart failure. Am J Cardiol. 2014;114(8):1257–63. doi:10.​1016/​j.​amjcard.​2014.​07.​056.PubMedCrossRef
Metadaten
Titel
Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure
verfasst von
Shweta R. Motiwala
Hanna K. Gaggin
Publikationsdatum
10.10.2016
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 5/2016
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-016-0303-y

Weitere Artikel der Ausgabe 5/2016

Current Heart Failure Reports 5/2016 Zur Ausgabe

Pharmacologic Therapy (W H W Tang, Section Editor)

Contemporary Controversies in Digoxin Use in Systolic Heart Failure

Management of Heart Failure (T Meyer, Section Editor)

Newer Therapies for Amyloid Cardiomyopathy

Epidemiology of Heart Failure (J Ho, Section Editor)

Burden of Heart Failure in Adults with Congenital Heart Disease

Comorbidities of Heart Failure (C Angermann, Section Editor)

Sleep-Disordered Breathing—Do We Have to Change Gears in Heart Failure?

Prevention of Heart Failure (MSJ Sutton, Section Editor)

Cardiometabolic Syndrome and Increased Risk of Heart Failure

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.